EUVIMEDEUVIMED entdecken
Crossref

Socioeconomic Factors and Initiation of Semaglutide or Tirzepatide Among Medicare Beneficiaries With Type 2 Diabetes

Sérgio R R Decker iD, Richard S Chaudhary, Kosuke Inoue, Yang Song, Chiadi E Ndumele iD, Sadiya S Khan iD, Dhruv S Kazi iD

Diabetes Care · 2026

DOI: 10.2337/dc25-1619 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diabetes Care, 2026. Verfasst von Sérgio R R Decker und 6 weiteren Autor:innen. Beteiligte Einrichtung: Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, MA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Medicare, Glucagon-Like Peptides, Hypoglycemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 19 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE Identifying social and economic factors associated with initiation of semaglutide or tirzepatide may inform strategies to support equitable uptake. RESEARCH DESIGN AND METHODS A cross-sectional study was conducted using 100% of Medicare claims of patients ≥65 years with type 2 diabetes mellitus (T2DM). The outcome was initiation of semaglutide or tirzepatide. We calculated adjusted odds ratios (aORs) for each exposure (self-reported race and ethnicity, dual enrollment in Medicare and Medicaid, rurality, and social vulnerability index), accounting for demographic and clinical characteristics. RESULTS Among 13,922,387 patients with T2DM, 673,776 (4.8%) initiated semaglutide or tirzepatide in 2023. Minoritized racial and ethnic identity (e.g., non-Hispanic Black compared with White; aOR 0.72; 95% CI 0.71–0.72), dual enrollment (aOR 0.90; 0.89–0.91), and residence in the most versus least vulnerable socially vulnerable neighborhoods (aOR 0.93; 0.92–0.93) were associated with lower initiation. CONCLUSIONS Minoritized racial and ethnic identity and adverse socioeconomic factors were associated with lower odds of initiation among Medicare beneficiaries with T2DM.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2MedicareGlucagon-Like PeptidesHypoglycemic AgentsHumansUnited StatesAgedMaleCross-Sectional StudiesFemaleSocioeconomic FactorsAged, 80 and overTirzepatide

Substanzen

Glucagon-Like PeptidesHypoglycemic AgentsTirzepatide

Autor:innen und Institutionen

  • Richard A. and Susan F. Smith Center for Outcomes Research, Beth Israel Deaconess Medical Center, Boston, MA.
  • Harvard Medical School, Boston, MA.
  • Department of Internal Medicine and MOVE Outcomes Research Lab, Moinhos de Vento Hospital, Porto Alegre, Brazil.
  • Department of Health Promotion and Behavioral Sciences, Kyoto University Graduate School of Medicine, Kyoto, Japan.
  • Hakubi Center, Kyoto University, Kyoto, Japan.
  • Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD.

ORCID-Profile: Sérgio R R Decker, Chiadi E Ndumele, Sadiya S Khan, Dhruv S Kazi

Zitieren

APA

Decker, S. R. R., Chaudhary, R. S., Inoue, K., Song, Y., Ndumele, C. E., Khan, S. S., & Kazi, D. S. (2026). Socioeconomic Factors and Initiation of Semaglutide or Tirzepatide Among Medicare Beneficiaries With Type 2 Diabetes. Diabetes Care. https://doi.org/10.2337/dc25-1619

Vancouver

Decker SRR, Chaudhary RS, Inoue K, Song Y, Ndumele CE, Khan SS, et al. Socioeconomic Factors and Initiation of Semaglutide or Tirzepatide Among Medicare Beneficiaries With Type 2 Diabetes. Diabetes Care. 2026. doi:10.2337/dc25-1619

BibTeX
@article{Decker2026,
  author = {Decker, Sérgio R R and Chaudhary, Richard S and Inoue, Kosuke and Song, Yang and Ndumele, Chiadi E and Khan, Sadiya S and Kazi, Dhruv S},
  title = {Socioeconomic Factors and Initiation of Semaglutide or Tirzepatide Among Medicare Beneficiaries With Type 2 Diabetes},
  journal = {Diabetes Care},
  year = {2026},
  doi = {10.2337/dc25-1619}
}
Kostenlos starten →